AFIRE Study Algorithm (AF + Stable CAD) Calculator
Clinical decision support
Review whether the stable coronary disease setting resembles the population studied in AFIRE. This is a decision aid, not an automated prescription.
How to interpret this tool
AFIRE studied patients with atrial fibrillation and stable coronary artery disease who had undergone PCI or CABG at least one year earlier, or had angiographically confirmed CAD not requiring revascularization. The trial compared rivaroxaban monotherapy with rivaroxaban plus a single antiplatelet agent.
The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline recommends OAC monotherapy over OAC plus a single antiplatelet agent for chronic coronary disease beyond one year after revascularization, or CAD not requiring revascularization, when there is no history of stent thrombosis, to reduce major bleeding.
Before changing therapy
- Confirm that oral anticoagulation is indicated for AF and that the selected agent and dose are appropriate for renal function, age, interactions, and local guidance.
- Check for recent ACS/PCI, prior stent thrombosis, complex coronary anatomy, recurrent ischemia, or another clear indication for antiplatelet therapy.
- Review bleeding risk and patient-specific ischemic risk with the treating clinician. Do not discontinue prescribed medication solely on the basis of this calculator.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.